ATE550031T1 - Zusammensetzungen und verfahren für die lipomodellierung - Google Patents

Zusammensetzungen und verfahren für die lipomodellierung

Info

Publication number
ATE550031T1
ATE550031T1 AT06772251T AT06772251T ATE550031T1 AT E550031 T1 ATE550031 T1 AT E550031T1 AT 06772251 T AT06772251 T AT 06772251T AT 06772251 T AT06772251 T AT 06772251T AT E550031 T1 ATE550031 T1 AT E550031T1
Authority
AT
Austria
Prior art keywords
methods
administering
fat
proximally
lipomodeling
Prior art date
Application number
AT06772251T
Other languages
English (en)
Inventor
Zofia Zukowska
Lydia Kuo
Stephen Baker
Michael Johnson
Edward Lee
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE550031T1 publication Critical patent/ATE550031T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polymerisation Methods In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06772251T 2005-06-06 2006-06-06 Zusammensetzungen und verfahren für die lipomodellierung ATE550031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68827105P 2005-06-06 2005-06-06
PCT/US2006/021873 WO2006133160A2 (en) 2005-06-06 2006-06-06 Compositions and methods for lipo modeling

Publications (1)

Publication Number Publication Date
ATE550031T1 true ATE550031T1 (de) 2012-04-15

Family

ID=37075271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06772251T ATE550031T1 (de) 2005-06-06 2006-06-06 Zusammensetzungen und verfahren für die lipomodellierung

Country Status (6)

Country Link
US (1) US20090317376A1 (de)
EP (2) EP1888101B1 (de)
AT (1) ATE550031T1 (de)
AU (1) AU2006255097B2 (de)
CA (1) CA2610022A1 (de)
WO (1) WO2006133160A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
KR20160025044A (ko) 2007-06-19 2016-03-07 키쎄라 바이오파마슈티컬즈 인코포레이티드 합성 담즙산 조성물, 방법 및 제조물
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
JP5722217B2 (ja) 2008-09-02 2015-05-20 アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用
US9308070B2 (en) 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
AU2010220830B2 (en) * 2009-03-02 2016-07-14 Nova Scientifica Llc Medicinal cosmetic lipoatrophy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20100249924A1 (en) * 2009-03-27 2010-09-30 Allergan, Inc. Bioerodible matrix for tissue involvement
ES2443045T5 (es) 2009-04-20 2021-05-10 Allergan Inc Hidrogeles de fibroína de seda y usos de éstos
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
HUE030138T2 (en) 2010-03-22 2017-04-28 Allergan Inc Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012024072A1 (en) 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
AU2012262047A1 (en) 2011-06-03 2014-01-16 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
PT2561876E (pt) 2011-08-23 2014-07-18 Kythera Biopharmaceuticals Inc Formulação do ácido deoxicólico e sais associados
BR112014000547B1 (pt) 2011-08-23 2021-11-09 Kythera Biopharmaceuticals, Llc Composição aquosa estável em precipitação
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
JP5186050B1 (ja) * 2012-02-24 2013-04-17 謙輔 山川 皮下組織および皮下脂肪組織増加促進用組成物
WO2016051219A1 (en) 2014-09-30 2016-04-07 Allergan Industrie, Sas Stable hydrogel compositions including additives
EP3653232A1 (de) 2015-02-13 2020-05-20 Allergan Industrie, SAS Implantate zur formung, verstärkung oder korrektur von gesichtszügen wie etwa dem kinn
WO2017079700A1 (en) 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
BR112022016333A2 (pt) * 2020-02-18 2022-10-04 Apyx Medical Corp Dispositivos, sistemas e métodos para detectar, e discernir entre, tecido adiposo e muscular durante procedimentos médicos

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4600710A (en) 1985-03-14 1986-07-15 G. D. Searle & Co. β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US6503277B2 (en) 1991-08-12 2003-01-07 Peter M. Bonutti Method of transplanting human body tissue
EP2283821A1 (de) 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
EP0824519A1 (de) 1995-05-10 1998-02-25 Pfizer Inc. Beta-adrenergische agonisten
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
FR2754709B1 (fr) * 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US5998458A (en) 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
BR9815499A (pt) * 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
US20050107327A1 (en) * 1997-12-19 2005-05-19 Hormos Medical Corporation Method for reducing overproduction of neuropeptide Y in an individual
US6017879A (en) 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
WO2000041671A2 (en) 1999-01-12 2000-07-20 T & T Pharmaceuticals, Ltd. Composition, device, and method for subcutaneous fat removal
AU2001238363A1 (en) 2000-02-15 2001-08-27 Zen Bio, Inc. Compositions for preventing cellulite in mammalian skin
DK1308439T3 (da) 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
ATE407924T1 (de) 2000-10-06 2008-09-15 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
WO2002060410A2 (en) 2001-01-30 2002-08-08 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
PE20021002A1 (es) 2001-02-02 2002-12-06 Takeda Chemical Industries Ltd Compuestos heterociclicos condensados
EP1236723A1 (de) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamid-Derivate verwendbar als Beta3 Agonisten und ihre pharmazeutischen Anwendungen
EP1385508B1 (de) 2001-03-27 2008-05-21 Merck & Co., Inc. Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
SE0103476D0 (sv) 2001-10-18 2001-10-18 Markus Heilig New use
EP1338595B1 (de) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthin-Derivate als DPP-IV-Inhibitoren
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20040185069A1 (en) 2003-03-22 2004-09-23 Gupta Shyam K. Hydroxycitric acid derivatives for body slimming and tone firming compositions
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2004091540A2 (en) 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
NZ543274A (en) 2003-05-14 2007-12-21 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists
WO2005014073A1 (en) 2003-08-08 2005-02-17 Contura Sa Implantable hydrogel with resorbable shell for use as an endoprothesis
WO2005030754A1 (en) 2003-09-24 2005-04-07 Janssen Pharmaceutica, N.V. Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity
US20050089555A1 (en) 2003-10-24 2005-04-28 Aventis Pharma Deutschland Gmbh Medicinal targeted local lipolysis
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing

Also Published As

Publication number Publication date
CA2610022A1 (en) 2006-12-14
EP1888101B1 (de) 2012-03-21
WO2006133160A2 (en) 2006-12-14
EP2356997A1 (de) 2011-08-17
US20090317376A1 (en) 2009-12-24
AU2006255097B2 (en) 2012-02-09
WO2006133160A3 (en) 2007-05-03
HK1118445A1 (en) 2009-02-13
EP1888101A2 (de) 2008-02-20
AU2006255097A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
WO2006133160A3 (en) Compositions and methods for lipo modeling
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
AU2007257423A8 (en) Purine analogs
EP2177224A3 (de) Mittel zur Vorbeugung und Behandlung von Erkrankungen mit RyR-Rezeptormodulation
ECSP10010335A (es) Pirrolo-pirimidinas y pirrolo-piridinas
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
NO20071272L (no) Modulatorer av muskarine reseptorer.
CR20170070A (es) Composición, método y preparación del ácido biliar sintético
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
TW200602031A (en) Antiinflammatory and pain-relieving agent for external, use
ATE500855T1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE547009T1 (de) Zusammensetzungen und verfahren zur förderung von körperfettverlust
NZ594698A (en) Method and means for producing tissues and tissues obtained
WO2008143876A3 (en) Agents and assays for modulating neurodegeneration
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
AR052071A1 (es) Procedimientos para modular las actividades del receptor nicotinico alfa 7 de acetilcolina